Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.


Journal

Oncology
ISSN: 1423-0232
Titre abrégé: Oncology
Pays: Switzerland
ID NLM: 0135054

Informations de publication

Date de publication:
2020
Historique:
received: 14 01 2020
accepted: 29 01 2020
pubmed: 26 2 2020
medline: 12 5 2020
entrez: 26 2 2020
Statut: ppublish

Résumé

Few studies have examined the details of nutritional status in patients with unresectable hepatocellular carcinoma (u-HCC) undergoing systemic chemotherapy with lenvatinib. We evaluated the prognostic/predictive value of nutritional status using Onodera's prognostic nutritional index (O-PNI) for overall survival among patients with u-HCC treated with lenvatinib. Three-hundred and seventy-five u-HCC patients treated with lenvatinib were enrolled (median age 72 years; Child-Pugh class A/B/C: n = 312/60/3; BCLC stage A/B/C/D: n = 2/159/212/2). We examined median survival time (MST) and time to progression (TTP) in all patients (n = 375), prognosis according to the O-PNI (high/low: >40/≤40) in 298 patients with lymphocyte findings, and the prognostic/predictive values of Child-Pugh stage, albumin-bilirubin (ALBI)/modified ALBI (mALBI) grade, and O-PNI for Chemotherapy grade (OPNIC grade 1/2/3: O-PNI >40/≤40 to >36/≤36). The MST and TTP were 16.6 and 8.0 months, respectively. The MST and TTP according to the O-PNI (>40/≤40) were "not reached" (NR)/12.4 months (p < 0.001) and 10.0/6.1 months (p = 0.012), respectively. There was a good correlation noted between ALBI score and O-PNI (r = -0.939, p < 0.001). The predictive value of the O-PNI for mALBI grade 2a was 36.0 (specificity/sensitivity = 0.894/0.942; area under the curve [AUC] = 0.978), while that for mALBI grade 1 was 39 (specificity/sensitivity = 0.920/0.929; AUC = 0.972), which was very similar to a high O-PNI. The MST analyzed with the OPNIC in the 298 patients was NR/16.2/10.4 months for OPNIC grade 1/2/3 (p < 0.001), respectively, and the c-index was 0.632, the same as that for mALBI grade (0.632), while that for Child-Pugh class was 0.571. OPNIC grading might have a potential for easy substitution of mALBI grading. A good nutritional status (OPNIC grade 1) or mALBI grade 1 is the best indication for lenvatinib use, while with an OPNIC grade 3, lenvatinib might be not suitable.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Few studies have examined the details of nutritional status in patients with unresectable hepatocellular carcinoma (u-HCC) undergoing systemic chemotherapy with lenvatinib. We evaluated the prognostic/predictive value of nutritional status using Onodera's prognostic nutritional index (O-PNI) for overall survival among patients with u-HCC treated with lenvatinib.
METHODS METHODS
Three-hundred and seventy-five u-HCC patients treated with lenvatinib were enrolled (median age 72 years; Child-Pugh class A/B/C: n = 312/60/3; BCLC stage A/B/C/D: n = 2/159/212/2). We examined median survival time (MST) and time to progression (TTP) in all patients (n = 375), prognosis according to the O-PNI (high/low: >40/≤40) in 298 patients with lymphocyte findings, and the prognostic/predictive values of Child-Pugh stage, albumin-bilirubin (ALBI)/modified ALBI (mALBI) grade, and O-PNI for Chemotherapy grade (OPNIC grade 1/2/3: O-PNI >40/≤40 to >36/≤36).
RESULTS RESULTS
The MST and TTP were 16.6 and 8.0 months, respectively. The MST and TTP according to the O-PNI (>40/≤40) were "not reached" (NR)/12.4 months (p < 0.001) and 10.0/6.1 months (p = 0.012), respectively. There was a good correlation noted between ALBI score and O-PNI (r = -0.939, p < 0.001). The predictive value of the O-PNI for mALBI grade 2a was 36.0 (specificity/sensitivity = 0.894/0.942; area under the curve [AUC] = 0.978), while that for mALBI grade 1 was 39 (specificity/sensitivity = 0.920/0.929; AUC = 0.972), which was very similar to a high O-PNI. The MST analyzed with the OPNIC in the 298 patients was NR/16.2/10.4 months for OPNIC grade 1/2/3 (p < 0.001), respectively, and the c-index was 0.632, the same as that for mALBI grade (0.632), while that for Child-Pugh class was 0.571.
CONCLUSIONS CONCLUSIONS
OPNIC grading might have a potential for easy substitution of mALBI grading. A good nutritional status (OPNIC grade 1) or mALBI grade 1 is the best indication for lenvatinib use, while with an OPNIC grade 3, lenvatinib might be not suitable.

Identifiants

pubmed: 32097925
pii: 000506293
doi: 10.1159/000506293
doi:

Substances chimiques

Biomarkers, Tumor 0
Phenylurea Compounds 0
Quinolines 0
lenvatinib EE083865G2
Bilirubin RFM9X3LJ49
Serum Albumin, Human ZIF514RVZR

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

295-302

Informations de copyright

© 2020 S. Karger AG, Basel.

Auteurs

Atsushi Hiraoka (A)

Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan, hirage@m.ehime-u.ac.jp.

Takashi Kumada (T)

Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan.

Toshifumi Tada (T)

Department of Internal Medicine, Himeji Red Cross Hospital, Himeji, Japan.

Shinya Fukunishi (S)

Department of Gastroenterology, Osaka Medical College, Osaka, Japan.

Masanori Atsukawa (M)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.

Masashi Hirooka (M)

Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.

Kunihiko Tsuji (K)

Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.

Toru Ishikawa (T)

Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.

Koichi Takaguchi (K)

Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.

Kazuya Kariyama (K)

Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.

Ei Itobayashi (E)

Department of Gastroenterology, Asahi General Hospital, Asahi, Japan.

Kazuto Tajiri (K)

Department of Gastroenterology, Toyama University Hospital, Toyama, Japan.

Noritomo Shimada (N)

Division of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa, Japan.

Hiroshi Shibata (H)

Department of Gastroenterology, Tokushima Prefectural Central Hospital, Tokushima, Japan.

Hironori Ochi (H)

Hepatobiliary Center, Matsuyama Red Cross Hospital, Matsuyama, Japan.

Kazuhito Kawata (K)

Department of Hepatology, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Hidenori Toyoda (H)

Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan.

Hideko Ohama (H)

Department of Gastroenterology, Osaka Medical College, Osaka, Japan.

Akemi Tsutsui (A)

Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.

Norio Itokawa (N)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.

Korenobu Hayama (K)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.

Taeang Arai (T)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.

Michitaka Imai (M)

Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.

Shinichiro Nakamura (S)

Department of Internal Medicine, Himeji Red Cross Hospital, Himeji, Japan.

Kojiro Michitaka (K)

Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.

Yoichi Hiasa (Y)

Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.

Masatoshi Kudo (M)

Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH